Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 339Reproductive Biology and FertilityOvarian function and disordersOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

RETRACTED: Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study

Open access
Badawy, Ahmed, Elnashar, Aboubakr, El-Ashry, Mohamed, Shahat, May·2009·Fertility and Sterility
DOI 10.1016/j.fertnstert.2007.12.044
Open this paper in CoChat — free accountOpen PDF

Abstract

Objective To determine whether GnRHa administration before and during combination chemotherapy for breast cancer could preserve posttreatment ovarian function in young women or not. Design Prospective randomized controlled study. Setting Department of Obstetrics and Gynecology, Mansura University Hospital, Mansura, Egypt. Patient(s) Eighty patients with unilateral adenocarcinoma of the breast and with no metastasis who had undergone modified radical mastectomy or breast-conserving surgery plus full axillary lymph node dissection were included in the study. Patients were assigned randomly to receive combined GnRHa and chemotherapy or chemotherapy alone. One woman in each group dropped out. Main outcome measure(s) Return of spontaneous menstruation and ovulation. Hormonal changes (FSH, LH, E(2), P) during and after the course of treatment. Result(s) In the study group, 89.6% resumed menses and 69.2% resumed spontaneous ovulation within 3-8 months of termination of the GnRHa/chemotherapy cotreatment; 11.4% experienced hypergonadotrophic amenorrhoea and ovarian failure 8 months after treatment. In the control group (chemotherapy without GnRHa), 33.3% resumed menses and 25.6% resumed normal ovarian activity. The median FSH and LH concentrations, 6 months after completion of the GnRHa/chemotherapy cotreatment group, were significantly less than the control group. During the GnRHa/chemotherapy cotreatment the concentrations of FSH, LH, and P decreased to almost prepubertal levels. However, within 1-3 months after the last GnRHa injection, an increase in LH and FSH concentrations was detected, followed several weeks later in by an increase in P concentrations to within normal levels. Conclusion(s) GnRHa administration before and during combination chemotherapy for breast cancer may preserve posttreatment ovarian function in women <40 years. Long-term studies are required.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.fertnstert.2007.12.044This paper is marked retracted.

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

Items 101–200 of 339

Related

See all

Metadata

Authors
Badawy, A., Elnashar, A., El-Ashry, M., & Shahat, M.
Affiliations
  • Mansoura University (EG)
  • Benha University (EG)
Corresponding author
Badawy, Ahmed
ORCID
Venue
Fertility and Sterility
Publisher
Elsevier BV
Published
2009-03
Volume
91
Issue
3
Pages
694-697
ISSN
0015-0282 (ISSN-L)
DOI
10.1016/j.fertnstert.2007.12.044
OpenAlex
W2101897761
Cited by
331
References
15
Citations by year
2026: 4 · 2025: 4 · 2024: 2 · 2023: 5 · 2022: 5 · 2021: 9 · 2020: 5 · 2019: 14 · 2018: 12 · 2017: 18 · 2016: 14 · 2015: 21 · 2014: 23 · 2013: 31 · 2012: 50
FWCI
35.35
Type
journal article
Language
en
Status
Retracted
Update notices
Open access
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • Fertility and Sterility (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords
GnRH agonist, chemotherapy-induced ovarian damage, breast cancer, ovarian preservation, chemotherapy-induced amenorrhea, ovarian failure, FSH and LH levels, estrogen and progesterone, young women
MeSH terms
Adenocarcinoma, Adult, Amenorrhea, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Drug Administration Schedule, Estradiol, Female, Fertility Agents, Female, Humans, Infertility, Female, Luteinizing Hormone, Gonadotropin-Releasing Hormone, Lymph Node Excision, Mastectomy, Menstruation, Ovary, Ovulation, Progesterone, Prospective Studies, Time Factors, Primary Ovarian Insufficiency, Treatment Outcome, Chemotherapy, Adjuvant, Goserelin, Follicle Stimulating Hormone, Human

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.